Birtamimab

Summary

Birtamimab (CHEMBL3833345) is a phase-3 clinical-stage antibody; indicated across 2 conditions including hereditary amyloidosis and amyloidosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833345
Name	Birtamimab
Type	Antibody
Max phase	3

Also known as: Birtamimab, Hu2A4, NEOD001, BIRTAMIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hereditary amyloidosis	3	MONDO:0018634	MONDO:0019438
amyloidosis	2	MONDO:0019065	EFO:1001875

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02312206	PHASE3	TERMINATED	The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
NCT04973137	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
NCT01707264	PHASE1/PHASE2	COMPLETED	Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NCT02613182	PHASE2	TERMINATED	Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NCT02632786	PHASE2	COMPLETED	The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
NCT03154047	PHASE2	TERMINATED	Study in Subjects With Light Chain (AL) Amyloidosis
NCT03168906	PHASE2	TERMINATED	Renal AL Amyloid Involvement and NEOD001

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).